With the number of people with dementia in Australia expected to nearly double by 2054, the federal government is funding a new AU$50 million (US$32.76 million) biomedical and med-tech incubator program to develop new therapies, medical devices and digital health technologies to address dementia and cognitive decline.
Vandria SA has disclosed urolithin and fluorene derivatives acting as ferroptosis inhibitors and reported to be useful for the treatment of neurodegeneration and inflammatory disorders.
Voyager Therapeutics Inc. has announced the selection of a lead development candidate from its Friedreich’s ataxia program with collaborator Neurocrine Biosciences Inc.
A new cutting-edge blood-based biomarker test developed by researchers at Hong Kong University of Science and Technology can detect early Alzheimer’s disease (AD) and mild cognitive impairment (MCI), with accuracy rates surpassing 96% and 87% respectively, and could be a game changer in detecting and treading early AD.
Open Source Therapeutics has patented new aromatic substituent-containing (hetero) aryl-imidazole compounds acting as bifunctional epoxide hydrolase 2 (EPHX2; sEH) inhibitors.
South Korea’s MFDS gave regulatory clearance to SK Inc. C&C’s artificial intelligence (AI) solution to diagnose cerebral infarction called Medical Insight+ Brain Infarct on Feb. 22, as a class III device.
Enveric Biosciences Inc. has announced the discovery of multiple, promising novel compounds sourced using the company’s Psybrary platform and proprietary computational chemistry and artificial intelligence (AI) drug-discovery system (Psyai).
South Korean biopharmaceutical firm GNT Pharma Co. Ltd. on Feb. 13 reported positive findings from a domestic phase III trial of its neuroprotectant therapy, nelonemdaz (NEU-2000), for patients with acute ischemic stroke.
RSS
